Phuturdex › Diseases › Knee osteoarthritis
Drugs in development · updated 30 October 2026
Knee osteoarthritis: drugs in development
As of 30 October 2026 there are 41 active clinical trials (recruiting or ongoing, phases I–III) on 37 drugs for knee osteoarthritis. 20 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Hyaluronic Acid | III | 2 | NCT07736781 |
| NNC0487-0111 | III | 2 | NCT07509307 |
| Alpha Lipoic Acid | III | 1 | NCT07399743 |
| ArtrodarAC-203 | III | 1 | NCT04318041 |
| CLS2901C | III | 1 | NCT06549686 |
| Ecnoglutide InjectionXW003 injection | III | 1 | NCT07734311 |
| PTP-01 | III | 1 | NCT07219771 |
| Ribupatide | III | 1 | NCT07709910 |
| Allocetra | I–II | 1 | NCT06233474 |
| LY4065967 | II | 1 | NCT07641517 |
| Maltodextrin | II | 1 | NCT07189585 |
| NCR100 | I–II | 1 | NCT06741098 |
| PPV-06 | II | 1 | NCT06605963 |
| PTP-001 | II | 1 | NCT05100225 |
| Vutiglabridin | II | 1 | NCT06845553 |
| ANT-301 | I | 1 | NCT06539429 |
| AtibuclimabIC14 | I | 1 | NCT07481474 |
| BBM-A101 | I | 1 | NCT07198555 |
| FX201 | I | 1 | NCT04119687 |
| GNSC-001 | I | 1 | NCT05835895 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| DronabinolTetrahydrocannabinol, Delta-9-THC | III | 2 | NCT05335252 |
| Pentosan Polysulfate SodiumElmiron® | II–III | 2 | NCT04809376 |
| ColchicineColchicin, Lodoco® | III | 1 | NCT06578182 |
| GabapentinGralise®, Neurontin® | II–III | 1 | NCT07047040 |
| KetorolacAcuvail®, Sprix® | II–III | 1 | NCT07047040 |
| Solumedrol | II–III | 1 | NCT07703280 |
| Tranexamic AcidTransexamic acid, Lysteda® | III | 1 | NCT07825350 |
| Triamcinolone Acetonidezilretta, Kenalog { | II–III | 1 | NCT07151417 |
| CannabidiolEpidiolex, Epidyolex® | I–II | 3 | NCT06414473 |
| MetforminRiomet Er®, Glumetza® | II | 2 | NCT06096259 |
| DuloxetineDrizalma Sprinkle®, Cymbalta® | II | 1 | NCT07649291 |
| Insulin Isophane Human | I–II | 1 | NCT07757464 |
| InulinInulin And Sodium Chloride® | II | 1 | NCT07189585 |
| Recombinant Human Growth Hormone InjectionSomatropin, Human Growth Hormone | I–II | 1 | NCT07036003 |
| KetoprofenNexcede®, Actron® | I | 1 | NCT07319728 |
Sorted by most advanced phase and number of active trials. Showing 15 of 17 drugs.
All 37 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Broader categories
- Joint Diseases 6 drugs
- Arthritis 13 drugs
- Rheumatic Diseases 30 drugs
- Musculoskeletal disorder 22 drugs
- Osteoarthritis 20 drugs
- Neurologic Manifestations 15 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D020370 “Osteoarthritis, Knee”.